Table 1.

Cohort attrition stratified by treatment regimen

	Colistina	βL + βLI agent
	n = 6811	n = 7952
Patients ≥ 18 years of age	6505 (95.5%)	7891 (99.2%)
Inpatient hospitalization	6434 (94.5%)	7654 (96.3%)
Non-cystic fibrosis patients	4499 (66.1%)	7235 (91.0%)
Patients receiving ≥ 3 days of treatment	3320 (48.7%)	5713 (71.8%)
Patients w/any microbiological results	734 (10.8%)	1520 (19.1%)
Patients w/confirmed Gram negative pathogen	649 (9.5%)	1267 (15.9%)
Patients w/no evidence of ARF POA or dialysis prior to 1st dose	319 (4.7%)	657 (8.3%)
Propensity score matched 1:1	256 (3.8%)	256 (3.2%)

ARF acute renal failure, POA present on admission

^aStarting with patients receiving ≥ 1 day of treatment